Alexander G. Semenov, PhD, HyTest Ltd.
The newly FDA-approved heart failure drug (Entresto®) has caused significant excitement as the clinical studies have shown considerably better therapy outcomes for patients suffering from heart failure. As a result of its mode of action it has been suggested that only NT-proBNP should be measured when using Entresto therapy. However, one could argue that this suggestion may be based on an overly simplified model of a complex system involving different natriuretic peptides and their different forms. In this white paper, Dr. Alexander Semenov will discuss some of the issues that are associated with the Entresto therapy and natriuretic peptides.
Download the White paper here.